Pluri Inc. · NASDAQ:PLUR
Pluri — Corporate Update (October 2026)
24 slides from Pluri's corporate update, Oct 29, 2026
Slide 1: Company Update
1 CO M PANY PRESENTATI O N Company Update Yaky Yanay, Chief Executive Officer Alejandro Weinstein, Chairman of the Board of Directors OCTOBER 29, 2026 NASDAQ: PLUR TASE: PLUR CELL-BASED SOLUTIONS AT SCALE
Slide 2: Forward looking statement
DISCLAIMER Forward looking statement This presentation contains forward-looking statements within the Israeli Securities Law, 1968, the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as amended, regarding Pluri Inc. and/or its subsidiaries (collectively the
Slide 3: Two decades of cell science, manufacturing and clinical development
Two decades of cell science, manufacturing and clinical development 20+ years of cell expertise 800+ patients in clinical studies 200+ patents globally I–III clinical development phases PLUR Publicly traded Nasdaq IN-HOUSE COMMERCIAL-SCALE FACILITY Existing GMP manufacturing infrastructure PLURI | I
Slide 4: Pluri - agenda for today
TODAY’S DISCUSSION Pluri - agenda for today A cell-based technology company moving from platform development toward commercial execution TODAY’S UPDATE PLURI Cell-based solutions at scale ZEO: U.S. MARKET ACCESS A MORE COMMERCIAL PLURI Connecting Pluri’s technology & A shift toward commercialization
Slide 5: Three commercial engines. One core platform.
BUSINESS MODEL Three commercial engines. One core platform. U.S. COMMERCIAL Regenerative biologics Physician network + distribution | Commercialize / distribute AESTHETICS Cellav professional systems Clinics + distributors | Repeat product sales CDMO GMP cell manufacturing Biotech partners | Service
Slide 6: Perfect synergy, building U.S. Full vertical commercial platform
UPDATE AT A GLANCE Perfect synergy, building U.S. Full vertical commercial platform • Proprietary 3D cell expansion bioreactors • Established Florida physician relationships • FDA Phase I–III clinical experience • Best-in-class Product Portfolio • 200+ patents • Provider education Masterclasses, mar
Slide 7: A broader regenerative product platform
BEYOND CELLS A broader regenerative product platform Cell biology and controlled manufacturing create a foundation for multiple future formats Cells Living biologic systems with extensive clinical and manufacturing experience. Secretome Cell-secreted cytokines, proteins and growth factors. Extracell
Slide 8: Regenerative medicine enters the spotlight in professional sports
Regenerative medicine enters the spotlight in professional sports "Choosing PRP instead of stem cells is going to be the reason Pluri brings over 20 why Luka fails to fully recover in time." years of expertise to "PRP is like a Toyota Corolla. Stem cells are like a Ferrari." this emerging field. "MS
Slide 9: Joint Pluri + ZEO portfolio
Joint Pluri + ZEO portfolio In-market ZEO biologics, alongside Pluri platforms and candidates ZEO: PLURI’s CELL SECRETOME & IN MARKET PLATFORM EVs TODAY Umbilical Cord Stem Cells Orthopedics, Placenta cells HPCM pain, wound care Investigational cell therapies Placental cells conditioned media Patien
Slide 10: Why the Pluri-ZEO combination matters?
TRANSACTION RATIONALE Why the Pluri-ZEO combination matters? Commercial capabilities today; multiple market opportunities over time PLURI ZEO SCIENTIFIX Technology and manufacturing depth Existing U.S. commercial channel Proprietary cell-expansion platform, clinical- Products already in market, Flor
Slide 11: Regenerative Aesthetics $3.9B
Cellav / REGENERATIVE AESTHETICS Regenerative Aesthetics Professional topical products recommended and sold through clinical practices WHAT CLINICS OFFER HOW PRODUCTS REACH PATIENTS Skin care 01 Product supplier Sells professional products to Professional serums using EV/exosome or clinics and distr
Slide 12: Cellav - from sources to market-ready systems
REGENERATIVE AESTHETICS Cellav - from sources to market-ready systems Two source platforms translated into ingredients, professional systems and clinic-led home care SOURCE PLATFORMS PROFESSIONAL SYSTEMS HOME-CARE SYSTEMS PLACENTA-DERIVED EX18 Human placenta - HPCM Placento+ PlacentoPRO+ Placenta-de
Slide 13: Exosome-led brands show a meaningful commercial precedent
REGENERATIVE AESTHETICS Exosome-led brands show a meaningful commercial precedent Professional, largely self-pay aesthetics channels support repeat product purchasing ExoCoBio / BENEV (private) REVENUE | USD MILLIONS Illustrative ~$98M 98 FY2025 ExoCoBio group revenue 100 67 48 50 ~20 ~$63M 0 FY2025
Slide 14: Pluri-ZEO: existing biologics and future cell-based products
REGENERATIVE LONGEVITY Pluri-ZEO: existing biologics and future cell-based products A commercial U.S. presence paired with Pluri's investigational cell-development platform PLURI ZEO SCIENTIFIX TECHNOLOGY AND DEVELOPMENT PORTFOLIO PRODUCTS DESCRIBED AS IN MARKET Placenta-derived cell candidates Umbi
Slide 15: ZEO revenue: reported sales and illustrative growth
REGENERATIVE LONGEVITY ZEO revenue: reported sales and illustrative growth Revenue history through 2025, an illustrative 2026 estimate and potential expansion thereafter ZEO REVENUE 2027-2028: ILLUSTRATIVE ONLY USD MILLIONS | FY2023-FY2025 REPORTED ~8.0 5.20 4.56 4.62 2023 2024 2025 2026E* 2027 2028
Slide 16: New state legislation could expand the footprint to 56.6M
U.S. STEM CELL LEGISLATION LANDSCAPE New state legislation could expand the footprint to 56.6M Stem-cell access frameworks and proposals. Status: 28 October 2026 CURRENT BROADER-LAW STATES: 45.6M 13.4% of the U.S. population IF NJ AND NH BILLS BECOME LAW: 56.6M FFL 16.6% of the U.S. population Broad
Slide 17: CDMO: Monetizing infrastructure, know-how and available capacity
CDMO CDMO: Monetizing infrastructure, know-how and available capacity Specialized capability Capital efficiency Human, animal and plant-cell Leverages installed GMP expansion on one platform. infrastructure and technical teams. Strategic adjacency Revenue profile Creates relationships with Service,
Slide 18: Cell therapy CDMO: a $6.4B global market forecast by 2030
CDMO Cell therapy CDMO: a $6.4B global market forecast by 2030 Growing demand for specialized cell manufacturing and outsourced process development 25.7% GLOBAL CELL THERAPY CDMO | USD BILLIONS $8B $6.43B Estimated 2025-2030 CAGR $6B PLURICDMO CAPABILITIES $4B Cell expansion and process scale-up $2.
Slide 19: PluriCDMO: an expanding commercial revenue base
CDMO PluriCDMO: an expanding commercial revenue base Four active clients and a staged revenue ramp, with a longer-term direction of growth 4 ACTIVE CLIENTS ANNUAL CDMO REVENUE | USD MILLIONS $2-3M $2-3M ~$1M; 2027 indicative revenue range* $0.5M ANNOUNCED CUSTOMER PROGRAMS 2025 2026E 2027E 2028 2029
Slide 20: Capital structure- chairman-led acquisition of EIB loan
UPDATE AT A GLANCE Capital structure- chairman-led acquisition of EIB loan Pluri is aligning its capital structure and commercial infrastructure with its next phase Mr. Weinstein is an investor and entrepreneur with a track record of building, scaling and realizing value across healthcare, biotechno
Slide 21: Capital structure- chairman-led acquisition of EIB loan
UPDATE AT A GLANCE Capital structure- chairman-led acquisition of EIB loan Pluri is aligning its capital structure and commercial infrastructure with its next phase EIB LOAN Alejandro Weinstein, Pluri’s Chairman and largest shareholder, has agreed to acquire the EIB loan. Active investor and Chairma
Slide 22: Innovating the future of food & bio-farming
FOODTECH & BIO-FARMING Innovating the future of food & bio-farming Pluri contributes its technology to each venture in exchange for majority ownership, scaling value across multiple verticals Cultivated Meat Cultivated Cacao 58% Pluri Ownership Current valuation +$70M 79%Strategic JV Bühler partners
Slide 23: What investors should take away
KEY MESSAGES What investors should take away 1 Commercial direction is tangible ZEO, Cellav and CDMO provides revenue pathways. The EIB assignment is intended to create a more direct and 2 Financial alignment is improving flexible framework, while a long-term resolution is developed. Leadership conv
Slide 24: Thank you.
THANK YOU. Investor Q&A investor.relations@pluri-biotech.com www.pluri-biotech.com NASDAQ: PLUR | TASE: PLUR 24